Comparison of the efficacy and safety of the XELOX regimen versus the FOLFOX-4 regimen in metastatic colorectal carcinoma
DOI:
https://doi.org/10.18203/2320-6012.ijrms20261470Keywords:
XELOX, FOLFOX-4, Colorectal cancer, ChemotherapyAbstract
Background: Colorectal cancer is a major cause of cancer-related mortality worldwide. Common regimens such as FOLFOX-4 and XELOX are widely used in metastatic colorectal carcinoma (mCRC), differing in toxicity profiles and administration methods.
Methods: This quasi-experimental study included 60 patients with histologically confirmed unresectable mCRC treated at BSMMU from April 2021 to March 2022. Patients were equally assigned to two groups: Arm A received XELOX (oxaliplatin+capecitabine) and Arm B received FOLFOX-4 (oxaliplatin+leucovorin+5-FU). Tumor response and toxicity were assessed using WHO and CTCAE v 5.0 criteria.
Results: The median age was 52 years, with 70% male participants. Baseline characteristics were comparable (p> 0.05). At 12 weeks, partial response rates were 46.7% in XELOX and 53.3% in FOLFOX-4, with no significant difference (p=0.605). After treatment completion, partial response was 40.0% and 46.7%, respectively, while progressive disease was higher in XELOX (33.3% vs 20.0%; p=0.668). Median progression-free survival was similar (7.8 vs 8.2 months; p=0.65). Grade 3–4 neutropenia was significantly higher in FOLFOX-4 (40.0% vs 0%, p=0.003), with febrile neutropenia observed only in this group. XELOX showed higher rates of diarrhea (40.0%) and hand-foot syndrome (23.3%).
Conclusions: Both regimens demonstrated comparable efficacy. XELOX had more gastrointestinal toxicity, whereas FOLFOX-4 showed higher hematological toxicity. XELOX may be a suitable alternative where outpatient convenience is preferred.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
National Institute of Cancer Research and Hospital, 2020. Hospital Cancer Registry report 2015-2017. Dhaka, Bangladesh. 2020. Available at: NICRH Hospital Cancer Registry Report 2015–2017 PDF. Accessed on 24 January 2026.
Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10-32.
McQuade RM, Stojanovska V, Bornstein JC, Nurgali K. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem. 2017;24(15):1537-57.
De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938-47.
Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26(12):2006-12.
Alzahrani SM, Al Doghaither HA, Al-Ghafari AB, Pushparaj PN. 5-fluorouracil and capecitabine therapies for the treatment of colorectal cancer. Oncol Rep. 2023;50(4):175.
Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol. 2008;19(10):1720-6.
Zekri J, Baghdadi MA, Ibrahim RB, Meliti A, Sobahy TM. Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer. Ecancermedicalscience. 2022;16:1490.
Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer. 2011;105(1):58-64.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
Raza AM, Kamal M, Begum F, Yusuf MA, Mohammad D, Begum M, et al. Clinico-demographic characteristics of colorectal carcinoma in Bangladeshi patients. J Curr Adv Med Res. 2016;3(1):22-7.
Sato Y, Tsujinaka S, Miura T, Kitamura Y, Suzuki H, Shibata C. Inflammatory bowel disease and colorectal cancer: epidemiology, etiology, surveillance, and management. Cancers (Basel). 2023;15(16):4154.
Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer. 2011;128(3):682-90.
Guo Y, Xiong BH, Zhang T, Cheng Y, Ma L. XELOX vs FOLFOX in metastatic colorectal cancer: an updated meta-analysis. Cancer Invest. 2016;34(2):94-104.
Zhang C, Wang J, Gu H, Zhu D, Li Y, Zhu P, et al. Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: meta-analysis of randomized controlled trials. Oncol Lett. 2012;3(4):831-8.
Park YH, Kim BS, Ryoo BY, Yang SH. A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer. 2006;94(7):959-63.
Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol. 2002;13(12):1893-8.
Salah-Eldin MA, Ebrahim MA, Al-Ashry MS. Phase II study of capecitabine plus cisplatin in patients with gastric cancer. Anticancer Drugs. 2009;20(3):191-6.
Downloads
Published
How to Cite
Issue
Section
